On Jun 14, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) − a global manufacturer of high-end analytical instruments used within the academic & government, pharma/biotech, clinical diagnostic and industrial markets. The company currently carries a Zacks Rank #3 (Hold).
Bruker started 2016 on a promising note, with its first-quarter results beating the Zacks Consensus Estimate on both fronts. A strong year-over-year revenue upside was driven by the company’s enhanced operating performance and significant bottom-line improvement.
During the reported quarter, Bruker expanded its existing MALDI Biotyper workflow’s menu to include selected high-value resistance testing for clinical microbiology research. The company also launched MBT Biotargets and introduced new research use-only capabilities to the MALDI Biotyper product portfolio.
Further, other products that the company recently launched include the honey profiling module of the NMR FoodScreener solution and the latest version of NMR wine screener module. Together these products are expected to contribute significantly to Bruker’s revenues.
On the flip side, unfavorable currency translation continues to be a major dampener for the stock. Evidently, changes in foreign exchange rates impacted Bruker’s revenues by 0.9% in the first quarter of 2016. For 2016, management expects revenues to face a 1.6% reduction owing to unfavorable currency.
Moreover, widespread macroeconomic uncertainties prevailing in countries like the U.S., Russia and certain European nations in which Bruker operates might hamper its revenue growth significantly, in case of any further economic downturn. Competitive headwinds also continue to pose threats to the stock.
Key Picks in the Sector
Better-ranked medical stocks are ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On Jun 14, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) − a global manufacturer of high-end analytical instruments used within the academic & government, pharma/biotech, clinical diagnostic and industrial markets. The company currently carries a Zacks Rank #3 (Hold).
Bruker started 2016 on a promising note, with its first-quarter results beating the Zacks Consensus Estimate on both fronts. A strong year-over-year revenue upside was driven by the company’s enhanced operating performance and significant bottom-line improvement.
During the reported quarter, Bruker expanded its existing MALDI Biotyper workflow’s menu to include selected high-value resistance testing for clinical microbiology research. The company also launched MBT Biotargets and introduced new research use-only capabilities to the MALDI Biotyper product portfolio.
Further, other products that the company recently launched include the honey profiling module of the NMR FoodScreener solution and the latest version of NMR wine screener module. Together these products are expected to contribute significantly to Bruker’s revenues.
On the flip side, unfavorable currency translation continues to be a major dampener for the stock. Evidently, changes in foreign exchange rates impacted Bruker’s revenues by 0.9% in the first quarter of 2016. For 2016, management expects revenues to face a 1.6% reduction owing to unfavorable currency.
Moreover, widespread macroeconomic uncertainties prevailing in countries like the U.S., Russia and certain European nations in which Bruker operates might hamper its revenue growth significantly, in case of any further economic downturn. Competitive headwinds also continue to pose threats to the stock.
Key Picks in the Sector
Better-ranked medical stocks are ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ICUI - FREE
Get the latest research report on LMAT - FREE
Get the latest research report on BRKR - FREE